General MedicationsINTRAVENOUSGeneric

FENTANYL CITRATE

Standard Dose

EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview FENTANYL CITRATE is listed in Drugs@FDA under application 215870 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient FENTANYL CITRATE Form and strength SOLUTION;INTRAVENOUS - EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor EXELA PHARMA Submission history Latest submission status date: 2025-12-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview FENTANYL CITRATE is listed in Drugs@FDA under application 215870 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient FENTANYL CITRATE Form and strength SOLUTION;INTRAVENOUS - EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor EXELA PHARMA Submission history Latest submission status date: 2025-12-22 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.